Drug Discovery Informatics Market

The Drug Discovery Informatics Market is valued at USD 3.7 Bn in 2026 and is projected to reach USD 6.9 Bn,  growing at a CAGR of 9% by 2033.The growth of global drug discovery informatics market can be attributed to the increasing demand for advanced technologies for the identification and development of new drugs. In addition, the growing investments in R&D by pharmaceutical and biotechnology companies are also expected to fuel the growth of the market.

The drug discovery process is lengthy and expensive, making it essential that pharmaceutical companies invest in the most efficient and effective tools available. One such tool is drug discovery informatics, which helps researchers quickly and easily identify potential drug targets and develop new therapies. As the use of big data becomes more widespread, informatics has become critical to the discovery process. This raised demand for drug discovery informatics professionals is expected to drive employment growth over the next decade. The job openings are also expected to be excellent due to increased use of outsourcing by large pharmaceutical companies.

The growth comes as pharmaceutical companies continue to struggle with high costs and limited alternative options for treating certain diseases. However, qualified individuals can expect numerous opportunities in this growing field.

• Drug discovery informatics is designed to support the entire drug discovery process, from target identification to preclinical development and clinical trials
  
  
• The increasing complexity of the drug discovery process has driven the need for more sophisticated informatics tools and solutions
  
  
• Drug discovery informatics helps researchers identify new drug targets and develop better therapies faster and more efficiently and enables researchers to share data and collaborate more effectively across disciplines
  
  
• The use of informatics tools can help reduce the time and cost of drug discovery and help researchers identify promising new drugs and optimize their development pathway
  
  
• Manage the risk associated with drug development and help researchers make better decisions and optimize the drug discovery process
  
  
• Increasing use of big data and cloud-based solutions has driven demand for drug discovery informatics

Sequencing and Target Data Analysis to Continue Leading the Global Drug Discovery Informatics Market

The drug discovery informatics for sequencing analysis is important for the new drug entity and ease of handling of information from different sources. The sequence data handling can be difficult and time consuming if not done properly. Therefore, major end-users are making the use of informatics tools to improve the efficiency and quality of the work. Proper annotation and curation of the data is important for the analysis. Data management of the sequencing information is very important.  The use of informatics tools can help to improve the quality and efficiency of the work. The use of software such as EMBOSS can help to automate many of the tasks involved in the sequencing analysis. The software can help to improve the accuracy of the results and also reduce the time needed for the analysis.

Moreover, the drug discovery informatics market is witnessing rapidly growing demand for different tools and software as these tools can help to improve the quality and efficiency of work done on the data produced by the next generation sequencing.  The use of high throughput assays has become common with increasing automation in labs, but analyzing large amount of data generated by these assays can be complex. The use of informatics tools can help to streamline this process and improve the quality of data produced. The sequencing analysis following next generation sequencing is a resource intensive activity, but use of informatics tools can reduce the time needed for these activities.

Well-established Healthcare Infrastructure to Majorly Contribute to North America Drug Discovery Informatics Market

North America is considered to be the most advanced region in terms of technology adoption, due to which it has been a major contributor for the growth of the drug discovery informatics market. In addition, the presence of a large number of players in this region has led to significant technological innovations and product developments. The market is expected to create several opportunities for small and medium enterprises (SMEs) due to the high adoption rate of these tools by SMEs. Various government initiatives have also created new employment opportunities for informatics professionals.

The region is home to a number of well-established CROs, which helps to drive demand for informatics services. In addition, R&D expenditure by pharmaceutical and biopharmaceutical companies is on the rise in the region. North America is home to some of the leading CROs, including Parexel, Quintiles, Covance, Charles River Laboratories, CRI Worldwide, ICON plc, and Icon Clinical Research. Furthermore, presence of key clients such as Roche Diagnostics (US), Pfizer (US), Merck & Co. (US), and Eli Lilly and Company (US) is also fueling the demand for drug discovery informatics services in the region. Moreover, strong government support for R&D activities is also contributing to the growth of the market in North America. For instance, in the US the National Institutes of Health (NIH) spent nearly $37.5 billion on health-related research, and this is expected to drive the growth of the drug discovery informatics market in the region during the forecast period 2021-2027.

It has been observed that key players operating in North America drug discovery informatics market are focusing on collaborations and strategic alliances with regional and international companies to expand their geographical presence. For instance, in March 2016, Parexel entered into a strategic alliance with Shanghai-based WuXi AppTec to offer expanded services to clients in China. This alliance is expected to help the companies to capitalize on the increasing demand for drug discovery and development services in China.

Pharmaceutical Companies are Ramping up Investment in Drug Discovery Informatics Market

• Schrödinger, Inc.
• Cresset Group
• BIOVIA (Dassault Systèmes)
• Certara (formerly Tripos)
• OpenEye Scientific
• Genedata AG
• Dotmatics (Cignpost Diagnostics)
• ChemAxon (part of Optibrium)
• Optibrium Ltd.
• Benchling
• Insilico Medicine
• Exscientia
• Schrödinger (also R&D informatics)
• PerkinElmer, Inc.
• BioSolveIT GmbH

 

By Service Type

• In-house
• Outsourced

By Modality      

• Cloud-based Systems
• In-campus Platform

By Application  

• Data Sequencing
• Molecular Docking
• Identification and Validation Informatics
• Target Data Analysis
• Others

By End User      

• Pharmaceutical Companies
• Contract Research Organizations
• Biotechnology Companies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa